EUCTR2008-003322-42-BG进行中（未招募）不适用
A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48 Week, Study of Oral Recombinant sCT Compared to Calcitonin Nasal Spray in Postmenopausal Osteoporotic Women - A Comparison of Oral and Nasal Calcitonin in Postmenopausal Osteoporotic Women
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Female and age 45 or over.
- •Must have undergone the onset of spontaneous or surgical menopause. Spontaneous menopause is defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- •Diagnosis of osteoporosis on the basis of an axial lumbar spine, femoral neck or total hip BMD which is below the mean for premenopausal women by a magnitude of at least 2.5 SD or 2.0 SD, if there is a documented history of a vertebral fragility fracture.
- •Must have at least three contiguous lumbar vertebrae (L1-L4) that are evaluable by DXA for BMD that is, without fracture or significant degenerative disease, as determined by Bio-Imaging Technologies, Inc.
- •A body mass index (BMI) of not greater than 39 (BMI = weight [kg]/height[m]2).
- •No clinically significant abnormal findings in the medical history, physical exam or nasal exam.
- •No clinically significant abnormal laboratory values at the screening assessment.
- •Patients must give written informed consent after reading the Patient Information and Consent Form and having had the opportunity to discuss the study with the Investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of severe allergic disease.
- •History of metabolic and other bone diseases, including osteogenesis imperfecta, osteomalacia, and Paget's disease.
- •Vitamin D insufficiency defined as a 25 hydroxyvitamin D level <20 ng/mL.
- •Use of any intravenous bisphosphonate in the past 24 months, or >2 doses of intravenous bisphosphonate ever.
- •Use of oral bisphosphonate before randomization, including investigational bisphosphonates, unless:
- •less than 6 months of treatment and off for 6 months, or
- •6 to 12 months of treatment and off for 2 years, or
- •More than 12 months of treatment and off for 5 years
- •Use of denosumab, fluoride, or strontium, ever.
- •Use of parathyroid hormone analogs or other bone metabolic agents within 1 year preceding randomization.
- •Any condition or disease that may interfere with the ability to have a DXA scan or to evaluate a DXA scan, for example, severe osteoarthritis of the spine, spinal fusion, pedicle screws, history of vertebroplasty, or degenerative disease that results in insufficient number of evaluable lumbar vertebrae, or more than 1 lumbar vertebral fracture in L1 through L4.
- •More than 4 vertebral fractures in T4 through L4
- •Bilateral hip replacements
- •Use of anabolic steroids or androgens within 6 months preceding randomization.
- •Use of Vitamin D metabolites and analogs, (e.g., calcitriol) within 3 months preceding randomization. Note: Vitamin D supplementation is not exclusionary.
- •Use of estrogen or estrogen-related drugs, for example, tamoxifen, tibolone, or raloxifene within 3 months preceding randomization.
- •Use of calcineurin inhibitors [e.g., cyclosporine, tacrolimus], methotrexate, aromatase inhibitors andantiepileptic medications.
- •Use of coumadin within 4 weeks preceding randomization or heparin within 1 week preceding randomization.”
- •Chronic systemic treatment with glucocorticoids, hormone replacement therapy, calcitonin or any other medication within the previous three months which, in the opinion of the Investigator, would interfere with the study.
- •Clinically relevant abnormal history, physical findings or laboratory values at the pre-study screening assessment that could interfere with the objectives of the study or the safety of the patient.
- •Presence of acute or chronic illness or history of chronic illness which, in the judgment of the Investigator, makes participation in the study medically inappropriate.
- •Uncontrolled hypertension, significant gastrointestinal abnormalities, uncontrolled diabetes mellitus, significant coronary heart disease, any psychotic mental illness, chronic allergic rhinitis, asthma, uncorrected endocrine dysfunction, or significantly impaired hepatic, respiratory or renal function.
- •Participation in any other clinical study within the previous 1 month.
- •History of drug or alcohol abuse, or intake of more than 30 units of alcohol weekly.
- •Possibility that the patient will not cooperate with the requirements of the protocol.
- •Any nasal abnormality, such as nasal polyps, that, in the opinion of the Investigator, could interfere with absorption of intranasally administered test drug.
- •Known sensitivity to sCT or excipients.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48 Week, Study of Oral Recombinant Calcitonin (rsCT) Compared to Calcitonin Nasal Spray in Postmenopausal Osteoporotic Women - A Comparison of Oral and Nasal Calcitonin in Postmenopausal Osteoporotic WomeMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalPostmenopausal OsteoporosisEUCTR2008-003322-42-GBTarsa Therapeutics, Inc.550
进行中（未招募）
不适用
A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48 Week, Study of Oral Recombinant Calcitonin (rsCT) Compared to Calcitonin Nasal Spray in Postmenopausal Osteoporotic Women - A Comparison of Oral and Nasal Calcitonin in Postmenopausal Osteoporotic WomeMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalPostmenopausal OsteoporosisEUCTR2008-003322-42-HUTarsa Therapeutics, Inc.550
进行中（未招募）
不适用
A Randomized, Multiple-dose, Double-Blind, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Study to determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat Inhaler in Patients with Chronic Obstructive PulmonaryDisease (COPD) -Chronic Obstructive Pulmonary DiseaseEUCTR2005-000650-79-BEBoehringer Ingelheim Coordination Centre Belgium420
尚未招募
不适用
Compare the Efficacy and Safety of Budesonide andFormoterol Fumarate Dihydrate Inhalation Aerosol80/4.5 mcg per Actuation in Asthma patientsCTRI/2019/10/021627Deva Holding AS
已完成
2 期
A Randomized, Double-blind, Multiple Dose Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitisinflammatory bowel disease10017969Ulcerative ColitisNL-OMON39233Amgen30